亚洲癌症相关静脉血栓栓塞患者中非维生素K拮抗剂口服抗凝药与低分子肝素的比较
该多机构电子病历数据库队列研究纳入2012年1月1日至2019年1月31日期间1109例癌症相关静脉血栓栓塞患者,比较非维生素K拮抗剂口服抗凝药(529例,47.7%)与低分子肝素依诺肝素(580例,52.3%)的复发性静脉血栓栓塞或大出血复合终点。非维生素K拮抗剂口服抗凝药组复合终点发生75例(14.1%),依诺肝素组101例(17.4%),加权HR 0.77(95%CI 0.56-1.07;P=0.11)。12个月随访时两组静脉血栓栓塞复发风险相似(HR 0.62;95%CI 0.39-1.01;P=0.05),大出血风险相似(HR 0.80;95%CI 0.52-1.24;P=0.32),但非维生素K拮抗剂口服抗凝药组胃肠道出血风险显著更低(1.9% vs 7.1%;HR 0.29;95%CI 0.15-0.59;P<0.001)。作者认为需进一步前瞻性研究证实这些发现。
要点
- 在亚洲癌症相关静脉血栓栓塞患者中,非维生素K拮抗剂口服抗凝药与依诺肝素的复发性静脉血栓栓塞或大出血复合终点风险相似:加权HR 0.77(95%CI 0.56-1.07;P=0.11)。
- 12个月随访时两组静脉血栓栓塞复发风险相似:HR 0.62(95%CI 0.39-1.01;P=0.05),未达统计学显著。
- 12个月随访时两组大出血风险相似:HR 0.80(95%CI 0.52-1.24;P=0.32)。
- 非维生素K拮抗剂口服抗凝药组胃肠道出血风险显著低于依诺肝素组:10例(1.9%)vs 41例(7.1%);HR 0.29(95%CI 0.15-0.59;P<0.001)。
- 竞争风险分析结果与主要分析一致:复发性静脉血栓栓塞HR 0.68(95%CI 0.45-1.01;P=0.05);大出血HR 0.77(95%CI 0.51-1.16;P=0.21)。
适用人群与场景
- 台湾长庚研究资料库(多机构电子病历数据库)中2012年1月1日至2019年1月31日期间确诊癌症相关静脉血栓栓塞的1109例患者。
- 纳入患者中578例(52.1%)为女性,索引日期平均(标准差)年龄66.0(13.0)岁。
处置流程与药物剂量
- 暴露分组:529例(47.7%)接受非维生素K拮抗剂口服抗凝药(包括利伐沙班、阿哌沙班、艾多沙班或达比加群),580例(52.3%)接受低分子肝素依诺肝素。
研究设计与关键结果
- 研究设计:队列研究,使用台湾长庚研究资料库(多机构电子病历数据库),纳入1109例癌症相关静脉血栓栓塞患者,比较非维生素K拮抗剂口服抗凝药与依诺肝素。
- 主要终点(复发性静脉血栓栓塞或大出血复合终点):非维生素K拮抗剂口服抗凝药组75例(14.1%)vs 依诺肝素组101例(17.4%);加权HR 0.77(95%CI 0.56-1.07;P=0.11)。
- 12个月随访静脉血栓栓塞复发:HR 0.62(95%CI 0.39-1.01;P=0.05)。
- 12个月随访大出血:HR 0.80(95%CI 0.52-1.24;P=0.32)。
- 胃肠道出血:非维生素K拮抗剂口服抗凝药组10例(1.9%)vs 依诺肝素组41例(7.1%);HR 0.29(95%CI 0.15-0.59;P<0.001)。
- 竞争风险分析(将死亡作为竞争风险):复发性静脉血栓栓塞HR 0.68(95%CI 0.45-1.01;P=0.05);大出血HR 0.77(95%CI 0.51-1.16;P=0.21)。
证据类型、等级与局限
- 证据类型:队列研究(使用多机构电子病历数据库)。
- 局限:原文报告需进一步前瞻性研究证实这些发现。
对床旁实践的改变
- 作者认为,在真实世界实践中,亚洲癌症相关静脉血栓栓塞患者使用非维生素K拮抗剂口服抗凝药与使用低分子肝素依诺肝素相比,复发性静脉血栓栓塞或大出血风险相似。
- 作者认为,使用非维生素K拮抗剂口服抗凝药与显著更低的胃肠道出血率相关。
- 作者建议,需进一步前瞻性研究证实这些发现。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is unclear whether the clinical benefits associated with non-vitamin K antagonist oral anticoagulants (NOACs) are similar to those associated with low-molecular-weight heparins (LMWHs) in Asian individuals with cancer and acute venous thromboembolism (VTE).
OBJECTIVE: To compare the risk of recurrent thromboembolic events and bleeding associated with use of a NOAC vs use of the LMWH enoxaparin in Asian individuals with cancer-associated VTE.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted using data from the Chang Gung Research Database, a multi-institutional electronic medical records database in Taiwan. A cohort of 1109 patients with cancer-associated VTE were identified between January 1, 2012, and January 31, 2019. Data were analyzed from March 2019 through December 2020.
EXPOSURES: Receiving a NOAC (including rivaroxaban, apixaban, edoxaban, or dabigatran) or the LMWH enoxaparin.
MAIN OUTCOMES AND MEASURES: The primary outcomes were composite recurrent VTE or major bleeding. Stabilized inverse probability of treatment weighting was used to balance baseline covariates. We compared risks of recurrent VTE or major bleeding between groups using Cox proportional hazards models. In addition, we conducted an analysis using a Fine and Gray subdistribution hazard model that considered death as a competing risk.
RESULTS: Among 1109 patients with cancer and newly diagnosed VTE, 578 (52.1%) were women and the mean (SD) age at index date was 66.0 (13.0) years; 529 patients (47.7%) received NOACs and 580 patients (52.3%) received the LMWH enoxaparin. Composite recurrent VTE or major bleeding occurred in 75 patients (14.1%) in the NOAC group and 101 patients (17.4%) in the enoxaparin group (weighted hazard ratio [HR], 0.77; 95% CI, 0.56-1.07; P = .11). The groups had similar risk of VTE recurrence (HR, 0.62; 95% CI, 0.39-1.01; P = .05) and major bleeding (HR, 0.80; 95% CI, 0.52-1.24; P = .32) at 12 months of follow-up. However, taking a NOAC was associated with a significantly lower risk of gastrointestinal bleeding compared with receiving enoxaparin (10 patients [1.9%] vs 41 patients [7.1%]; HR, 0.29; 95% CI, 0.15-0.59; P < .001). Findings for both primary outcomes were consistent with competing risk analyses (recurrent VTE: HR, 0.68; 95% CI, 0.45-1.01; P = .05; major bleeding: HR, 0.77; 95% CI, 0.51-1.16; P = .21).
CONCLUSIONS AND RELEVANCE: This cohort study found that in real-world practice, among Asian patients with cancer-associated VTE, use of a NOAC was associated with a similar risk for recurrent VTE or major bleeding compared with use of the LMWH enoxaparin. Nonetheless, use of a NOAC was associated with a significantly lower rate of gastrointestinal bleeding. Further prospective studies are needed to confirm these findings.
参考来源
- Chen DY, Tseng CN, Hsieh MJ, et al. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. JAMA Netw Open. 2021. PMID: 33533929. doi:10.1001/jamanetworkopen.2020.36304
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。